Table 2.
Clinical and pathological features of control patients without liver diseases (CTRL) and patients with chronic hepatitis (CH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC); data are expressed as the median (range).
| Characteristics | Group 1 CTRL | Group 2 CH | Group 3 LC | Group 4 HCC |
|---|---|---|---|---|
| Number (n) | 40 | 50 | 46 | 47 |
| Gender (M/F) | 36/4 | 30/20 | 24/22 | 27/20 |
| Age (years) | 44 (23–63) | 52.5 (25–85) | 66.5 (30–86) | 73 (45–87) |
| Albumin (g/dl) | 4.7 (3.47–5.01) | 4.66 (4.0–4.9) | 3.4 (2.0–4.5) | 1.03 (0.24–5.56) |
| Bilirubin (mg/dl) total | 0.72 (0.52–1.0) | 0.75 (0.34–1.1) | 1.27 (0.15–5.89) | 1.03 (0.24–5.56) |
| Aspartate amino-transferase (IU/ml) | 18.7 (12.0–26.1) | 55 (25.0–173.0) | 70 (19.0–377.0) | 56 (12.0–204.0) |
| Alanine amino-transferase (IU/ml) | 16.2 (11.5–22.02) | 85 (31.0–251.0) | 57 (12.0–221.0) | 45 (12.0–230.0) |
| International normalized ratio (INR) | 0.92 (0.86–1.01) | 0.97 (0.91–1.07) | 1.24 (1.06–1.73) | 1.06 (0.82–1.75) |
| HBs Ag | – | 2 | 4 | 3 |
| HCV Ab | – | 38 | 32 | 34 |
| Alcoholism | – | None | 3 | 5 |
| Cryptogenic | – | 10 | 7 | 4 |
| Dysmetabolic | – | None | None | 1 |
| BCLC | ||||
| A | – | – | – | 21 |
| B | – | – | – | 9 |
| C | – | – | – | 8 |
| D | – | – | – | 5 |
| E | – | – | – | 4 |
| CHILD-PUGH | ||||
| A | – | – | 26 | – |
| B | – | – | 16 | – |
| C | – | – | 4 | – |
BCLC, Barcelona Clinic Liver Cancer group; HBs Ag, anti-hepatitis B surface antigen; HCV Ab, anti-hepatitis antibody.